Bristol-Meyers May Slash Non-Californians From Ongylza Row
A San Francisco judge said at a hearing Monday he'll likely deny Bristol-Meyers Squibb Co. and Astrazeneca Pharmaceuticals LP's bid to end two product liability suits over the diabetes drug Onglyza...To view the full article, register now.
Already a subscriber? Click here to view full article